Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2011

View Archived Issues

Sinovac Biotech obtains GMP certificate in Mexico for two vaccines

Takeda antioxidant response element activator shows promise in experimental colitis

CHDI Foundation discloses new kynurenine 3-monooxygenase inhibitors

Hungarian company presents novel agents for tuberculosis

New agent exploits Warburg effect and shows promise in renal cell cancer models

Acetylon Pharmaceuticals prepares novel HD6 inhibitors

Novel beta-secretase 1 inhibitors synthesized by Amgen

NIH to support studies of Lpath immunotherapy in diabetic neuropathy

New voltage-gated sodium channel modulators presented by GSK

Primary endpoints met in phase III trial of Hisamitsu Pharmaceutical oxybutynin formulation

NexBio reports data from phase II trial of DAS-181

Omthera Pharmaceuticals begins phase III ESPRIT trial

Pulmatrix secures funding for COPD and CF programs

NanoViricides' lead HIVCide shows sustained anti-HIV effects in animal study

FDA extends review of Regeneron's BLA for Eylea

FDA approved new strengths of Lupron Depot-PED allowing administration every 3 months

Nabi Biopharmaceuticals receives another milestone payment from Fresenius

Genetically altered T cells eradicate chronic lymphocytic leukemia cells in patients

New compounds reported for hepatitis C

PharmAthene receives Department of Defense contract for nerve agent medical countermeasure program

Kuros Biosurgery advances European trial of dural sealant KUR-023

Clavis reports interim results from phase II trial of elacytarabine/idarubicin combination

Rhythm Pharmaceuticals begins phase I study in diabetic gastroparesis

Qiagen and Pfizer collaborate on companion diagnostic for investigational lung cancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...